|
|
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) |
|
Price: $15.3000
$0.45 
3.030%
|
| Day's High:
| $16.07990074157715
| Week Perf:
| -39.31 %
|
| Day's Low: |
$ 15.24 |
30 Day Perf: |
-40.74 % |
| Volume (M): |
11,439,761 |
52 Wk High: |
$ 39.89 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$27.14 |
| Open: |
$15.55 |
52 Wk Low: |
$13.81 |
|
|
| Market Capitalization (Millions $) |
1,539 |
| Shares
Outstanding (Millions) |
101 |
| Employees |
1,371 |
| Revenues (TTM) (Millions $) |
670 |
| Net Income (TTM) (Millions $) |
-609 |
| Cash Flow (TTM) (Millions $) |
50 |
| Capital Exp. (TTM) (Millions $) |
11 |
Business Description
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of rare and ultra-rare genetic diseases. The company's mission is to provide novel treatments for these rare diseases where there is unmet medical need.
The company was founded in 2010 by Emil Kakkis, who is a pioneer in the field of rare diseases. Ultragenyx started as a small startup and has grown to become one of the leading rare disease biotech companies in the industry. It is headquartered in Novato, California, USA, and has operations in Europe as well.
Ultragenyx is known for its expertise in developing and commercializing rare disease therapies. The company has a robust pipeline of programs that are aimed at addressing a range of rare diseases. Some of the key therapeutic areas the company is focused on include metabolic disorders, skeletal disorders, neurological disorders, and immunology.
One of the company's top products is Mepsevii (vestronidase alfa), which is an enzyme replacement therapy for the treatment of a rare genetic disorder called mucopolysaccharidosis VII (MPS VII). This condition is caused by a deficiency in beta-glucuronidase, which leads to the accumulation of certain complex sugars in the body tissues and organs. Mepsevii works by replacing the missing enzyme in the patient's body, thereby reducing the accumulation of complex sugars and improving the patient's symptoms.
Another product under development by Ultragenyx is DTX301, a gene therapy product for the treatment of ornithine transcarbamylase (OTC) deficiency. OTC deficiency is a rare genetic disorder that affects the body's ability to break down ammonia, leading to its build-up in the blood and tissues. DTX301 works by introducing a healthy copy of the OTC gene into the patient's liver cells, which helps to restore the body's ability to break down ammonia.
Ultragenyx has a strong commitment to research and innovation, and it is constantly exploring new approaches to treat rare diseases. The company has a team of highly experienced professionals who are dedicated to bringing innovative medicines to patients with rare diseases. It has also established partnerships with other companies and organizations in the industry to advance its research and development programs.
In summary, Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that is dedicated to the development and commercialization of innovative therapies for the treatment of rare and ultra-rare genetic diseases. The company has a broad pipeline of rare disease programs, and it is committed to advancing its research and development efforts to bring new treatments to patients in need.
Company Address: 60 Leveroni Court Novato 94949 CA
Company Phone Number: 483-8800 Stock Exchange / Ticker: NASDAQ RARE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Tue, Sep 9 2025 7:12 AM UTC
Ultragenyx Pharmaceutical Inc. has reported positive longer-term data from a Phase 3 clinical study evaluating DTX401, an adeno-associated virus (AAV) gene therapy, for the treatment of Glycogen Storage Disease Type Ia (GSDIa). This article summarizes the outcomes observed at Week 96 of the study, highlighting significant reductions in dietary cornstarch intake while mainta...
|
| Announcement
Published Wed, Jul 23 2025 2:42 PM UTC
Investor Alert: Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc. Amidst Unfavourable Market Performance The Pomerantz Law Firm has initiated an investigation into claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), in light of recent developments concerning the company’s share performance. This comes after reports indicating that U...
|
| Management Announcement
Published Wed, Mar 19 2025 9:00 PM UTC
Ultragenyx Pharmaceutical Inc. Strengthens Workforce and Growth Potential Through Strategic Stock Grant InitiativesOn March 19, 2025, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in therapies for rare and ultrarare diseases, announced the granting of 21,806 restricted stock units (RSUs) to 16 newly hired non-executive officers. Thi...
|
| Shares
Published Wed, Feb 19 2025 9:30 PM UTC
Ultragenyx Enhances Workforce with Stock Incentives - What This Means for ShareholdersNOVATO, Calif. Feb. 19, 2025 In a strategic move aimed at attracting top talent, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), known for pioneering treatments for rare and ultra-rare diseases, announced the issuance of 23,760 restricted stock units (RSUs) to 10 newly hired non-executive ...
|
| Shares
Published Fri, Jan 17 2025 9:30 PM UTC
In a strategic move to bolster its management team, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a prominent player in the biopharmaceutical sector focused on developing therapies for rare diseases, announced the grant of restricted stock units (RSUs) to newly hired non-executive officers. This latest grant, reported on January 17, 2025, involves 7,750 RSUs awarded to eigh...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-6.12 $ |
| Revenues (TTM) |
6.66 $
|
| Cash Flow (TTM) |
0.5 $ |
| Cash |
4.11 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
488,481 |
| Net
Income per Employee (TTM) |
-444,143 |
| Receivable Turnover Ratio (TTM) |
5.19 |
| Inventory Turnover Ratio (TTM) |
2.15 |
| Asset Turnover Ratio (TTM) |
0.5 |
|
|
| Per Share |
|
| Earnings (TTM) |
-6.12 $
|
| Revenues (TTM) |
6.66 $ |
| Cash Flow (TTM) |
0.5 $ |
| Cash |
4.11 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| Product Revenue |
|
 65.44 % |
of total Revenue |
| Product Revenue Crysvita |
|
33.82 % |
of total Revenue |
| Product Revenue Dojolvi |
|
13.24 % |
of total Revenue |
| Product Revenue Evkeeza |
|
13.24 % |
of total Revenue |
| Product Revenue Mepsevii |
|
5.15 % |
of total Revenue |
| Royalty revenue |
|
34.56 % |
of total Revenue |
| Royalty revenue Crysvita |
|
34.56 % |
of total Revenue |
| North America |
|
43.38 % |
of total Revenue |
| Latin America |
|
30.88 % |
of total Revenue |
| Europe Middle East and Africa |
|
22.79 % |
of total Revenue |
| Asia-Pacific |
|
2.94 % |
of total Revenue |
| Royalty revenue Kyowa Kirin Collaboration Royalty Revenue in North American Territory |
|
19.85 % |
of total Revenue |
| Non-cash royalty revenue Kyowa Kirin Collaboration Royalty Revenue in North American Territory |
|
8.82 % |
of total Revenue |
| Non-cash royalty revenue Kyowa Kirin Collaboration Royalty Revenue in European Territory |
|
5.88 % |
of total Revenue |
| Collaboration and Royalty Kyowa Kirin Collaboration |
|
68.38 % |
of total Revenue |
| Collaboration and Royalty Kyowa Kirin Collaboration Royalty Revenue in North American Territory |
|
28.68 % |
of total Revenue |
| Product sales |
|
65.44 % |
of total Revenue |
| Product sales Kyowa Kirin Collaboration |
|
33.82 % |
of total Revenue |
| |
On February 13 2025 the Ultragenyx Pharmaceutical Inc provided following guidance
nnUltragenyx Pharmaceutical Inc. Overview and Financial Highlights for 2024nn
On February 13, 2025, Ultragenyx Pharmaceutical Inc. released its financial results for the fourth quarter and the entirety of fiscal year 2024, along with a comprehensive corporate update.
The company reported a robust total revenue of $560 million for 2024, surpassing their previously set guidance. This notable achievement underscores the strong market performance and demand for their key treatments. Among the highlights, Crysvita generated impressive revenue of $410 million, while Dojolvi contributed $88 million to the total.
2024 Total Revenue reached $560 million, exceeding previ...
|
|
|
2.88%